[{"address1": "601 Brickell Key Drive", "address2": "Suite 1000", "city": "Miami", "state": "FL", "zip": "33131", "country": "United States", "phone": "650 460 8308", "website": "https://www.summittxinc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.", "fullTimeEmployees": 105, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert W. Duggan", "age": 79, "title": "Co-CEO & Executive Chairman", "yearBorn": 1944, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mahkam  Zanganeh D.D.S., M.B.A.", "age": 53, "title": "Co-CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 657809, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Manmeet Singh Soni", "age": 45, "title": "COO, CFO & Director", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 591499, "exercisedValue": 0, "unexercisedValue": 248000}, {"maxAge": 1, "name": "Prof. Dame Kay Davies DBE, FRS CBE", "age": 72, "title": "Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bhaskar  Anand", "age": 45, "title": "Chief Accounting Officer & Head of Finance", "yearBorn": 1978, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Abby Guzman Murphy", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Divya  Chari", "age": 55, "title": "Head of Global Clinical Operations", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dave  Gancarz", "title": "Chief Business & Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Betty Y. Chang Ph.D.", "title": "Head of Research, Oncology & Inflammation", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fong  Clow", "title": "Chief Biometrics Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 10, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 19.46, "open": 19.68, "dayLow": 19.68, "dayHigh": 21.54, "regularMarketPreviousClose": 19.46, "regularMarketOpen": 19.68, "regularMarketDayLow": 19.68, "regularMarketDayHigh": 21.54, "beta": -0.974, "forwardPE": -70.86666, "volume": 2531620, "regularMarketVolume": 2531620, "averageVolume": 5038540, "averageVolume10days": 2477370, "averageDailyVolume10Day": 2477370, "marketCap": 15623760896, "fiftyTwoWeekLow": 1.64, "fiftyTwoWeekHigh": 33.89, "fiftyDayAverage": 19.2167, "twoHundredDayAverage": 9.2084, "currency": "USD", "enterpriseValue": 15186908160, "floatShares": 109934113, "sharesOutstanding": 734889984, "sharesShort": 15446534, "sharesShortPriorMonth": 20729487, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.021, "heldPercentInsiders": 0.84626997, "heldPercentInstitutions": 0.10232, "shortRatio": 2.68, "shortPercentOfFloat": 0.1329, "impliedSharesOutstanding": 756416000, "bookValue": 0.269, "priceToBook": 79.03346, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -161692992, "trailingEps": -0.11, "forwardEps": -0.3, "enterpriseToEbitda": -105.764, "52WeekChange": 10.044156, "SandP52WeekChange": 0.39389753, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SMMT", "underlyingSymbol": "SMMT", "shortName": "Summit Therapeutics Inc.", "longName": "Summit Therapeutics Inc.", "firstTradeDateEpochUtc": 1425565800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d8568743-2bb7-3bc5-b04d-4193fee0ce0a", "messageBoardId": "finmb_11611587", "gmtOffSetMilliseconds": -14400000, "currentPrice": 21.26, "targetHighPrice": 45.0, "targetLowPrice": 5.0, "targetMeanPrice": 28.25, "targetMedianPrice": 31.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 325468992, "totalCashPerShare": 0.449, "ebitda": -143592000, "totalDebt": 108705000, "quickRatio": 2.329, "currentRatio": 2.346, "debtToEquity": 55.725, "returnOnAssets": -0.31011, "returnOnEquity": -1.0276899, "freeCashflow": -28683376, "operatingCashflow": -97492000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]